EP3108012A4 - Mir-320e and colorectal cancer - Google Patents

Mir-320e and colorectal cancer Download PDF

Info

Publication number
EP3108012A4
EP3108012A4 EP15752265.7A EP15752265A EP3108012A4 EP 3108012 A4 EP3108012 A4 EP 3108012A4 EP 15752265 A EP15752265 A EP 15752265A EP 3108012 A4 EP3108012 A4 EP 3108012A4
Authority
EP
European Patent Office
Prior art keywords
mir
colorectal cancer
colorectal
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15752265.7A
Other languages
German (de)
French (fr)
Other versions
EP3108012A1 (en
Inventor
Ajay Goel
Lucia PEREZ-CARBONELL
C. Richard Boland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of EP3108012A1 publication Critical patent/EP3108012A1/en
Publication of EP3108012A4 publication Critical patent/EP3108012A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Primary Health Care (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • General Business, Economics & Management (AREA)
  • Business, Economics & Management (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP15752265.7A 2014-02-18 2015-02-18 Mir-320e and colorectal cancer Withdrawn EP3108012A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461941340P 2014-02-18 2014-02-18
PCT/US2015/016285 WO2015126886A1 (en) 2014-02-18 2015-02-18 Mir-320e and colorectal cancer

Publications (2)

Publication Number Publication Date
EP3108012A1 EP3108012A1 (en) 2016-12-28
EP3108012A4 true EP3108012A4 (en) 2017-10-11

Family

ID=53878893

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15752265.7A Withdrawn EP3108012A4 (en) 2014-02-18 2015-02-18 Mir-320e and colorectal cancer

Country Status (4)

Country Link
US (2) US10260105B2 (en)
EP (1) EP3108012A4 (en)
CA (1) CA2939343A1 (en)
WO (1) WO2015126886A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11521736B1 (en) * 2016-06-13 2022-12-06 DynamiCare Health, Inc. System and method for encouraging therapeutic psychosocial activity
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120065098A1 (en) * 2006-07-13 2012-03-15 Department Of Health And Human Services Method of predicting chemotherapy effectiveness in colon adenocarcinoma patients, using mir-21

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2586455B1 (en) 2006-01-05 2014-06-25 The Ohio State University Research Foundation MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors
ES2448491T3 (en) 2006-03-02 2014-03-14 The Ohio State University Research Foundation MicroRNA expression profile associated with pancreatic cancer
CA2683314A1 (en) 2007-04-11 2008-10-23 Merck & Co., Inc. Isolated nucleic acid molecules corresponding to micro rna 145 (mirna-145) and their use in treating colon cancer
US8216784B2 (en) 2007-07-25 2012-07-10 University Of Louisville Research Foundation, Inc. Cancer-derived microvesicle-associated microrna as a diagnostic marker
US7993831B2 (en) 2007-09-14 2011-08-09 Asuragen, Inc. Methods of normalization in microRNA detection assays
WO2009140670A2 (en) 2008-05-16 2009-11-19 Veridex, Llc Methods for assessing colorectal cancer and compositions for use therein
US9068974B2 (en) 2008-11-08 2015-06-30 The Wistar Institute Of Anatomy And Biology Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
US10927415B2 (en) 2008-11-26 2021-02-23 The Johns Hopkins University Methods for identifying cancer risk
EP2625293A4 (en) 2010-10-08 2014-03-19 Baylor Res Inst Micrornas (mirna) as biomakers for the identification of familial and non-familial colorectal cancer
EP2681336A4 (en) 2011-03-02 2014-11-19 Groove Biopharma Corp Enhanced biodistribution of oligomers
RU2626540C2 (en) * 2011-04-18 2017-07-28 Диамир, Ллс Methods for pathological changes detection in organ or system of organs
NO3051026T3 (en) 2011-10-21 2018-07-28
EP2771487A1 (en) * 2011-10-27 2014-09-03 Asuragen, INC. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors
US20130164279A1 (en) 2011-12-22 2013-06-27 Baylor Research Institute Micro RNA-148A as a Biomarker for Advanced Colorectal Cancer
AU2012358200B2 (en) 2011-12-22 2018-08-30 Baylor Research Institute Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120065098A1 (en) * 2006-07-13 2012-03-15 Department Of Health And Human Services Method of predicting chemotherapy effectiveness in colon adenocarcinoma patients, using mir-21

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FRANKLIN G. BERGER ET AL: "Thymidylate synthase as a chemotherapeutic drug target: Where are we after fifty years?", CANCER BIOLOGY & THERAPY, vol. 5, no. 9, 1 September 2006 (2006-09-01), US, pages 1238 - 1241, XP055402496, ISSN: 1538-4047, DOI: 10.4161/cbt.5.9.3414 *
JUNIUS SALENDO ET AL: "Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g", RADIOTHERAPY AND ONCOLOGY, vol. 108, no. 3, 1 September 2013 (2013-09-01), Ireland, pages 451 - 457, XP055402374, ISSN: 0167-8140, DOI: 10.1016/j.radonc.2013.06.032 *
KEUN HUR ET AL: "Su1880: Identification of a novel metastasis-specific miRNA signature in human colorectal cancer", GASTROENTEROLOGY, vol. 142, no. 5, 1 May 2012 (2012-05-01), US, pages S - 525, XP055402376, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(12)62016-2 *
S.-Z. JIA ET AL: "Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis", HUMAN REPRODUCTION, vol. 28, no. 2, 1 February 2013 (2013-02-01), pages 322 - 330, XP055127856, ISSN: 0268-1161, DOI: 10.1093/humrep/des413 *
SALENDO ET AL: "Supplementary Table 1: Diagnostic and prognostic microRNAs in stage II colon cancer", CANCER RESEARCH, 68(15), 1 August 2008 (2008-08-01), XP055402697, Retrieved from the Internet <URL:http://ars.els-cdn.com/content/image/1-s2.0-S0167814013003113-mmc3.xlsx> [retrieved on 20170831] *
SCHEPELER TROELS ET AL: "Diagnostic and prognostic microRNAs in stage II colon cancer", CANCER RESEARCH, AACR - AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 68, no. 15, 1 August 2008 (2008-08-01), pages 6416 - 6424, XP002529939, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-07-6110 *

Also Published As

Publication number Publication date
US20170067115A1 (en) 2017-03-09
CA2939343A1 (en) 2015-08-27
US20190316207A1 (en) 2019-10-17
WO2015126886A1 (en) 2015-08-27
EP3108012A1 (en) 2016-12-28
US10260105B2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
EP3286361A4 (en) Cancer neoepitopes
EP3364949A4 (en) Cancer vaccines
EP3380101A4 (en) Eif4-a-inhibiting compounds and methods related thereto
EP3280738A4 (en) Cancer neoepitopes
EP3161135A4 (en) Plant-endophyte combinations and uses therefor
EP3193892A4 (en) Personalized cancer vaccines and methods therefor
EP3099171A4 (en) Dihydropteridinone derivatives and uses thereof
EP3092286A4 (en) Ethylene-to-liquids systems and methods
EP3156499A4 (en) Colorectal cancer detection kit or device, and detection method
EP3149037A4 (en) Anti-her2 glycoantibodies and uses thereof
EP3334706A4 (en) Pillararenes and uses thereof
EP3154972A4 (en) Azamophinan derivatives and use thereof
EP3200815A4 (en) Methods and compositions for treating cancer
EP3177292A4 (en) Compounds and methods for treating cancer
EP3177147A4 (en) Dihydropteridinone derivatives and uses thereof
EP3202909A4 (en) Cancer specific-splicing ribozyme and use thereof
EP3089992A4 (en) Compositions and methods for imaging cancer
EP3183578B8 (en) Methods for the early detection of colorectal cancer
EP3182132A4 (en) Cancer evaluation method and cancer evaluation system
EP3105238A4 (en) Prodrug compounds and their uses
EP3193878A4 (en) Compounds and methods
EP3119427A4 (en) Methods and materials for treating cancer
EP3119426A4 (en) Methods and materials for treating cancer
EP3096610A4 (en) Egg-breaking systems and methods
EP3213769A4 (en) Transdermal-absorption-promoter and transdermal-absorption-promoting supplement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20160825

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PEREZ-CARBONELL, LUCIA

Inventor name: BOLAND, C. RICHARD

Inventor name: GOEL, AJAY

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170908

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101AFI20170904BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180731

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYLOR RESEARCH INSTITUTE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/6886 20180101AFI20200306BHEP

INTG Intention to grant announced

Effective date: 20200330

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200811